<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659737</url>
  </required_header>
  <id_info>
    <org_study_id>20071433</org_study_id>
    <nct_id>NCT00659737</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting</brief_title>
  <official_title>A Randomized, Double-blind Comparison of Oral Aprepitant Alone Versus Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexel University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Drexel University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent evidence suggests multiple drug therapy is superior to single agents. The study
      compares the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time,
      and unplanned hospital admission in patients with high risk for PONV treated with oral
      aprepitant with or without transdermal scopolamine preoperatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative nausea and vomiting (PONV) is a serious problem complicating surgery. PONV has
      an overall incidence of 30% and a 70% incidence in high-risk patients. PONV yields unplanned
      hospital admission, pulmonary aspiration, esophageal rupture, electrolyte abnormalities,
      dehydration, and delayed discharge from the postanesthesia care unit (PACU). Additional use
      of resources costs the health care industry hundreds of millions of dollars annually. Patient
      satisfaction is greatly improved when PONV is prevented.4 PONV etiology is multifactorial and
      the treatment is multimodal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Postoperative Nausea and Vomiting</measure>
    <time_frame>0-24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Aprepitant pill and placebo transdermal patch at least 1 hour prior to surgical procedure.
Emend (Aprepitant) + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Scopolamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Aprepitant pill and Scopolamine transdermal patch at least 1 hour prior to surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>40mg tablet</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <other_name>Emend (Aprepitant) + Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <description>1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days</description>
    <arm_group_label>Scopolamine</arm_group_label>
    <other_name>Scopolamine + Emend (Aprepitant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be between 18 and 65 years of age.

          -  Patient's ASA (American Society of Anesthesiologist) class must be between 1 and 3.

          -  If patient is currently on oral contraceptive to prevent pregnancy, she must be
             willing to use a back up form of birth control for one month post study.

          -  Patient must have 1 FACTOR to qualify

               -  Female Sex

               -  History of PONV

               -  Motion Sickness

               -  Non-Smoker

               -  Intended Use of Post Operative Opioids

        Exclusion Criteria:

          -  Patients with a history of vomiting due to middle ear infection, nervous system
             disorder, or any other condition.

          -  The surgical procedure is less than 1 hour.

          -  The patient is pregnant or breast feeding.

          -  The patient has taken antiemetic medication in previous 24 hours.

          -  Patients with narrow-angle glaucoma.

          -  Allergy to belladonna alkaloids.

          -  Hypersensitivity to barbiturates.

          -  Patient taking any of the following medications:

               -  Orap

               -  Seldane

               -  Hismanal

               -  Propulsid

               -  Phenytoin

               -  Phenothiazines

               -  Tricyclic Antidepressants

               -  Meperidine

               -  Tolbutamide

               -  Aluminum and Magnesium Trisilicate-containing Antacids

               -  Anti-Cholinergics

               -  Coumadin

          -  Male patients with prostate hypertrophy.

          -  Patients with severe hepatic disease.

          -  Patients on Chemotherapy and taking Aprepitant.

          -  Patients with fever.

          -  Patients with sepsis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Horrow, MD</last_name>
    <role>Study Director</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <results_first_submitted>March 27, 2014</results_first_submitted>
  <results_first_submitted_qc>March 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2014</results_first_posted>
  <last_update_submitted>May 1, 2014</last_update_submitted>
  <last_update_submitted_qc>May 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-operative Nausea and Vomiting (PONV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aprepitant and Placebo Transdermal Patch</title>
          <description>Oral Aprepitant pill 40 mg tablet and placebo transdermal patch at least 1 hour prior to surgical procedure.</description>
        </group>
        <group group_id="P2">
          <title>Aprepitant and Scopolamine Transdermal Patch</title>
          <description>Oral Aprepitant pill, 40 mg tablet and Scopolamine transdermal patch, 1.5 mg patch delivering transdermally in vivo approximately 1.0mg over 3 days, at least 1 hour prior to surgical procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aprepitant and Placebo Transdermal Patch</title>
          <description>Oral Aprepitant pill, 40 mg tablet and placebo transdermal patch at least 1 hour prior to surgical procedure.</description>
        </group>
        <group group_id="B2">
          <title>Aprepitant and Scopolamine Transdermal Patch</title>
          <description>Oral Aprepitant pill, 40 mg tablet and Scopolamine transdermal patch, 1.5 mg patch delivering transdermally in vivo approximately 1.0mg over 3 days, at least 1 hour prior to surgical procedure</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="11.27"/>
                    <measurement group_id="B2" value="46.3" spread="11.06"/>
                    <measurement group_id="B3" value="46.8" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postoperative Nausea and Vomiting</title>
        <time_frame>0-24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant and Placebo Transdermal Patch</title>
            <description>Oral Aprepitant pill, 40 mg tablet and placebo transdermal patch at least 1 hour prior to surgical procedure.</description>
          </group>
          <group group_id="O2">
            <title>Aprepitant and Scopolamine Transdermal Patch</title>
            <description>Oral Aprepitant pill, 40 mg tablet and Scopolamine transdermal patch, 1.5 mg patch delivering transdermally in vivo approximately 1.0mg over 3 days, at least 1 hour prior to surgical procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Nausea and Vomiting</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0-24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aprepiatnt</title>
          <description>Oral Aprepitant pill and placebo transdermal patch at least 1 hour prior to surgical procedure.
Emend (Aprepitant) + Placebo: 40mg tablet</description>
        </group>
        <group group_id="E2">
          <title>Scopolamine</title>
          <description>Oral Aprepitant pill and Scopolamine transdermal patch at least 1 hour prior to surgical procedure.
Scopolamine + Emend (Aprepitant): 1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="57"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Green</name_or_title>
      <organization>Drexel university</organization>
      <phone>215-762-1524</phone>
      <email>micheal.green@drexelmed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

